TTY has always been active in expanding its business internationally. To date, TTY’s commercial teams and subsidiaries have been developed and established in the world, and TTY’s in-house developed & manufactured products have also been marketed in more than 18 countries around the globe.
In 2004, TTY decided to activate the establishment of various internationalized capabilities in European market for the strategic goal of internationalization.
In 2005, TTY established the department of international business development, actively building its global sales network. Today, TTY has promoted its pharmaceutical products beyond Taiwan, and successfully marketed its self-developed products to various countries in Europe, America, Africa, Asia and South East Asia.
In March 2009, all items of TTY Chung-Li Factory passed the EU inspection. TTY Chung-Li factory became the first factory with EU verification in Taiwan. Later in September, TTY obtained the first permit license of the anticancer generic drug, Docetaxel in Europe. On top of its achievement in EU, TTY will focus on developing American markets at the next stage. Furthermore, same year in August, TTY and to-BBB, a pharmaceutical company based in Netherlands, activated the co-development of brain-targeted drug, Liposomal Doxorubicin, and both companies announced the establishment of joint venture in Taiwan with the aim to jointly develop the new liposomal drug product.
Besides dedicating to expansion in new markets and existing markets, TTY continuously enhances its organizational strength and its influences in global market through new drug and technology licensing with its strategic partners.